Literature DB >> 18369634

Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT.

Christian Plathow1, Michael Klopp, Christian Thieke, Felix Herth, Andreas Thomas, Astrid Schmaehl, Ivan Zuna, Hans-Ulrich Kauczor.   

Abstract

To evaluate and compare early therapy response according to RECIST (response evaluation criteria in solid tumours) and modified RECIST criteria using MRI techniques in patients with malignant pleural mesothelioma (MPM) in comparison with CT. Fifty patients with MPM (32 male/18 female) were included in this study. Early therapy response was evaluated after 9 weeks [three of six chemotherapy (CHT)] cycles. Additionally patients were examined before chemotherapy, 4 weeks after early therapy response evaluation and after six cycles to evaluate diagnostic follow-up. RECIST and modified RECIST criteria were applied using CT and MRI (HASTE, VIBE, T2-TSE sequences). In MRI additionally a volumetric approach measuring tumour weight (overall segmented tumour volume) was applied. Additionally vital capacity (VC) was measured for correlation. Image interpretation was performed by three independent readers independently and in consensus. The 'gold standard' was follow-up examination. Twenty-eight patients showed partial response, 12 patients stable disease and 10 patients progressive disease at early therapy response evaluation. In the follow-up these results remained. For MRI, in 46 cases patients were identically classified using RECIST and modified RECIST criteria. Modified RECIST criteria were identically classified as gold standards in all cases, whereas using RECIST criteria in four cases there was a mismatch (partial response vs. stable disease). Modified RECIST kappa values showed better interobserver variability compared with RECIST criteria (kappa=0.9-1.0 vs. 0.7-1.0). For CT, in 44 cases patients were identically classified using RECIST and modified RECIST criteria. Modified RECIST criteria were identically classified as in gold standards in 48 out of 50 patients, whereas using RECIST criteria in 6 cases there was a mismatch (partial response vs. stable disease). Modified RECIST kappa values showed better interobserver variability compared with RECIST criteria (kappa=0.9-1.0 vs. 0.6-1.0). Modified RECIST criteria especially in combination with high-resolution MRI is a very accurate and reproducible technique to correctly evaluate early therapy response in MPM.

Entities:  

Mesh:

Year:  2008        PMID: 18369634     DOI: 10.1007/s00330-008-0918-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  26 in total

1.  Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.

Authors:  R T Heelan; V W Rusch; C B Begg; D M Panicek; J F Caravelli; C Eisen
Journal:  AJR Am J Roentgenol       Date:  1999-04       Impact factor: 3.959

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic.

Authors:  H Svanholm; H Starklint; H J Gundersen; J Fabricius; H Barlebo; S Olsen
Journal:  APMIS       Date:  1989-08       Impact factor: 3.205

4.  [Detection of pulmonary nodules with breath-hold magnetic resonance imaging in comparison with computed tomography].

Authors:  J F Schäfer; J Vollmar; F Schick; M D Seemann; P Kamm; B Erdtmann; C D Claussen
Journal:  Rofo       Date:  2005-01

5.  Fast T1- and T2-weighted pulmonary MR-imaging in patients with bronchial carcinoma.

Authors:  M Both; J Schultze; M Reuter; B Bewig; R Hubner; I Bobis; R Noth; M Heller; J Biederer
Journal:  Eur J Radiol       Date:  2005-03       Impact factor: 3.528

Review 6.  Morphologic and functional imaging of malignant pleural mesothelioma.

Authors:  Masaki Yamamuro; Victor H Gerbaudo; Ritu R Gill; Francine L Jacobson; David J Sugarbaker; Hiroto Hatabu
Journal:  Eur J Radiol       Date:  2007-10-22       Impact factor: 3.528

Review 7.  Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.

Authors:  Zhen J Wang; Gautham P Reddy; Michael B Gotway; Charles B Higgins; David M Jablons; Mohan Ramaswamy; Randall A Hawkins; W Richard Webb
Journal:  Radiographics       Date:  2004 Jan-Feb       Impact factor: 5.333

8.  Measurement of diaphragmatic length during the breathing cycle by dynamic MRI: comparison between healthy adults and patients with an intrathoracic tumor.

Authors:  Christian Plathow; Christian Fink; Sebastian Ley; Michael Puderbach; Monica Eichinger; Astrid Schmähl; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2004-05-01       Impact factor: 5.315

9.  Asbestos-related pleural disease: value of dedicated magnetic resonance imaging techniques.

Authors:  Marc-André Weber; Michael Bock; Christian Plathow; Klaus Wasser; Christian Fink; Ivan Zuna; Astrid Schmähl; Irina Berger; Hans-Ulrich Kauczor; Stefan O Schoenberg
Journal:  Invest Radiol       Date:  2004-09       Impact factor: 6.016

10.  Evaluation of pleural disease using MR and CT. With special reference to malignant pleural mesothelioma.

Authors:  A Knuuttila; L Kivisaari; A Kivisaari; M Palomäki; P Tervahartiala; K Mattson
Journal:  Acta Radiol       Date:  2001-09       Impact factor: 1.701

View more
  13 in total

1.  A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria.

Authors:  Anne S Tsao; Linda Garland; Mary Redman; Kemp Kernstine; David Gandara; Edith M Marom
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

2.  Adrenal gland volume measurement in septic shock and control patients: a pilot study.

Authors:  Stephanie Nougaret; B Jung; S Aufort; G Chanques; S Jaber; B Gallix
Journal:  Eur Radiol       Date:  2010-06-04       Impact factor: 5.315

Review 3.  Volumetric assessment in malignant pleural mesothelioma.

Authors:  David J Murphy; Ritu R Gill
Journal:  Ann Transl Med       Date:  2017-06

4.  Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Authors:  Daniel C Christoph; Bernadette Reyna Asuncion; Celine Mascaux; Cindy Tran; Xian Lu; Murry W Wynes; Thomas C Gauler; Jeremias Wohlschlaeger; Dirk Theegarten; Volker Neumann; Rodrigo Hepp; Stefan Welter; Georgios Stamatis; Andrea Tannapfel; Martin Schuler; Wilfried E Eberhardt; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

5.  A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.

Authors:  Valerie W Rusch; Ritu Gill; Alan Mitchell; David Naidich; David C Rice; Harvey I Pass; Hedy L Kindler; Marc De Perrot; Joseph Friedberg
Journal:  Ann Thorac Surg       Date:  2016-09-02       Impact factor: 4.330

Review 6.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

7.  Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.

Authors:  Darragh Halpenny; Micheal Raj; Andreas Rimner; Junting Zheng; Marinela Capanu; Michelle S Ginsberg
Journal:  Eur Radiol       Date:  2019-01-28       Impact factor: 5.315

8.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

9.  Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.

Authors:  Valerie W Rusch; Dorothy Giroux
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 10.  RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline.

Authors:  Els L van Persijn van Meerten; Hans Gelderblom; Johan L Bloem
Journal:  Eur Radiol       Date:  2009-12-22       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.